GlassScriptPhysician profile
Jane M Raymond
NPI 1518968825
$2,159.45
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $2,079 · 2020: $68.31 · 2021: $11.92.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $1,521.65 | 2019 | |
| Genentech USA, INC. | $406.13 | 2019 | |
| Lilly USA, LLC | $98.21 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $32.75 | 2019-2020 | |
| Aurobindo Pharma USA, INC. | $26.21 | 2020 | |
| E.R. Squibb & Sons, L.L.C. | $25.81 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $12.69 | 2020 | |
| Clovis Oncology, INC. | $12.04 | 2019 | |
| Seagen INC. | $12.04 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 |
3 companies reported research payments only; those appear in the research section below.
Research and ownership
$6,119.07 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jane Raymond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.